Keywords: Pfizer, Sutent, Pancreatic cancer, Resarch, Regulatory filing

Pfizer’s Sutent shows progress-free survival in patients with pancreatic neuroendocrine tumors

Article | 25 January 2010

Print This

Global pharmaceutical behemoth Pfizer says that final results from a randomized Phase III trial of its kidney cancer drug Sutent ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in